The effects of CYP2C19 genotype polymorphism and clopidogrel resistance on ischemic event occurrence in patients with peripheral arterial disease undergoing revascularization: A prospective cohort study
Authors:
Open Access
- 17 February 2024
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 236, 37-50
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 65 references indexed in Scilit:
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 UpdateClinical Pharmacology & Therapeutics, 2013
- Switching Acute Coronary Syndrome Patients From Prasugrel to ClopidogrelJACC: Cardiovascular Interventions, 2013
- Extended international (IOTF) body mass index cut‐offs for thinness, overweight and obesityPediatric Obesity, 2012
- Management of peripheral arterial interventions with mono or dual antiplatelet therapy—the MIRROR study: a randomised and double-blinded clinical trialEuropean Radiology, 2012
- Clopidogrel “Resistance”: Where are We Now?Cardiovascular Therapeutics, 2011
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsCirculation, 2011
- Predictors of Biochemical Aspirin and Clopidogrel Resistance in Patients With Ischemic StrokeJournal of Stroke and Cerebrovascular Diseases, 2011
- Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular DiseaseYonsei Medical Journal, 2011
- Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active MetaboliteDrug Metabolism and Disposition, 2010
- Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrelVascular Medicine, 1998